Intravitreal Bevacizumab (Avastin ®) in the Treatment of Neovascular Glaucoma

To describe a case series of neovascular glaucoma (NVG) caused by central retinal vein occlusion (CRVO) that was treated with intravitreal bevacizumab (IVB; Avastin ®). Retrospective interventional case series. Six consecutive patients with NVG and a refractory, symptomatic elevation of intraocular...

Full description

Saved in:
Bibliographic Details
Published in:American journal of ophthalmology 2006-12, Vol.142 (6), p.1054-1056
Main Authors: Iliev, Milko E., Domig, Diego, Wolf-Schnurrbursch, Ute, Wolf, Sebastian, Sarra, Gian-Marco
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Angiogenesis Inhibitors - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Bevacizumab
Biological and medical sciences
Combined Modality Therapy
Female
Glaucoma
Glaucoma, Neovascular - drug therapy
Glaucoma, Neovascular - etiology
Glaucoma, Neovascular - surgery
Humans
Injections
Intraocular Pressure - drug effects
Iris - surgery
Laser Coagulation
Male
Medical sciences
Miscellaneous
Ophthalmology
Pain
Retinal Vein Occlusion - complications
Retrospective Studies
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Vitreous Body
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To describe a case series of neovascular glaucoma (NVG) caused by central retinal vein occlusion (CRVO) that was treated with intravitreal bevacizumab (IVB; Avastin ®). Retrospective interventional case series. Six consecutive patients with NVG and a refractory, symptomatic elevation of intraocular pressure (IOP) and pronounced anterior segment congestion received IVB (1.25 mg/0.05 ml). Diode laser cyclophotocoagulation was carried out only if pressure was controlled insufficiently by topical medication. Follow-up examinations occurred at four to 16 weeks. IVB resulted in a marked regression of anterior segment neovascularization and relief of symptoms within 48 hours. IOP decreased substantially in three eyes; in the other three eyes, adjuvant cyclophotocoagulation was necessary. No side effects were observed. Panretinal photocoagulation (PRP) was performed as soon as feasible, five to 12 weeks after IVB treatment. IVB leads to a rapid regression of iris and angle neovascularization and should be investigated more thoroughly as an adjunct in the management of NVG.
ISSN:0002-9394
1879-1891
DOI:10.1016/j.ajo.2006.06.066